|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
McGuire WP, Hoskins WJ, Brady MF, et al:
Cyclophosphamide and cisplatin compared with paclitaxel and
cisplatin in patients with stage III and stage IV ovarian cancer. N
Engl J Med. 334:1–6. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Markman M, Bundy BN, Alberts DS, et al:
Phase III trial of standard-dose intravenous cisplatin plus
paclitaxel versus moderately high-dose carboplatin followed by
intravenous paclitaxel and intraperitoneal cisplatin in
small-volume stage III ovarian carcinoma: an intergroup study of
the Gynecologic Oncology Group, Southwestern Oncology Group and
Eastern Cooperative Oncology Group. J Clin Oncol. 19:1001–1007.
2001.PubMed/NCBI
|
|
4
|
Wei SH, Chen CM, Strathdee G, et al:
Methylation microarray analysis of late-stage ovarian carcinomas
distinguishes progression-free survival in patients and identifies
candidate epigenetic markers. Clin Cancer Res. 8:2246–2252.
2002.PubMed/NCBI
|
|
5
|
Jackson JR, Seed MP, Kircher CH,
Willoughby DA and Winkler JD: The codependence of angiogenesis and
chronic inflammation. FASEB J. 11:457–465. 1997.PubMed/NCBI
|
|
6
|
Balkwill F and Mantovani A: Inflammation
and cancer: back to Virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation and cancer. Cell. 140:883–899. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Assoian RK and Sporn MB: Type beta
transforming growth factor in human platelets: release during
platelet degranulation and action on vascular smooth muscle cells.
J Cell Biol. 102:1217–1223. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dubernard V, Arbeille BB, Lemesle MB and
Legrand C: Evidence for an alpha-granular pool of the cytoskeletal
protein alpha-actinin in human platelets that redistributes with
the adhesive glycoprotein thrombospondin-1 during the exocytotic
process. Arterioscler Thromb Vasc Biol. 17:2293–22305. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Allensworth SK, Langstraat CL, Martin JR,
et al: Evaluating the prognostic significance of preoperative
thrombocytosis in epithelial ovarian cancer. Gynecol Oncol.
130:499–504. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Unal D, Eroglu C, Kurtul N, Oguz A and
Tasdemir A: Are neutrophil/lymphocyte and platelet/lymphocyte rates
in patients with non-small cell lung cancer associated with
treatment response and prognosis? Asian Pac J Cancer Prev.
14:5237–5242. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Feng JF, Huang Y, Zhao Q and Chen QX:
Clinical significance of preoperative neutrophil lymphocyte ratio
versus platelet lymphocyte ratio in patients with small cell
carcinoma of the esophagus. Scientific World Journal.
5043652013.PubMed/NCBI
|
|
13
|
Wang D, Yang JX, Cao DY, Wan XR, Feng FZ,
Huang HF, Shen K and Xiang Y: Preoperative neutrophil-lymphocyte
and platelet-lymphocyte ratios as independent predictors of
cervical stromal involvement in surgically treated endometrioid
adenocarcinoma. Onco Targets Ther. 6:211–216. 2013.PubMed/NCBI
|
|
14
|
Absenger G, Szkandera J, Pichler M, et al:
A derived neutrophil to lymphocyte ratio predicts clinical outcome
in stage II and III colon cancer patients. Br J Cancer.
109:395–400. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cedrés S, Torrejon D, Martínez A, et al:
Neutrophil to lymphocyte ratio (NLR) as an indicator of poor
prognosis in stage IV non-small cell lung cancer. Clin Transl
Oncol. 14:864–869. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Absenger G, Szkandera J, Stotz M, et al:
Preoperative neutrophil-to-lymphocyte ratio predicts clinical
outcome in patients with stage II and III colon cancer. Anticancer
Res. 33:4591–4594. 2013.PubMed/NCBI
|
|
17
|
National Cancer Institute of USA, . Stage
Information for Ovarian Epithelial Cancer. Available at. http://www.cancer.gov/cancertopics/pdq/treatment/ovarianepithelial/HealthProfessional/page3Accessed.
December 19–2014.
|
|
18
|
Watanabe T, Shibata M, Nishiyama H, et al:
Serum levels of rapid turnover proteins are decreased and related
to systemic inflammation in patients with ovarian cancer. Oncol
Lett. 7:373–377. 2014.
|
|
19
|
McMillan DC, Canna K and McArdle CS:
Systemic inflammatory response predicts survival following curative
resection of colorectal cancer. Br J Surg. 90:215–219. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pierce BL, Ballard-Barbash R, Bernstein L,
et al: Elevated biomarkers of inflammation are associated with
reduced survival among breast cancer patients. J Clin Oncol.
27:3437–3444. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kodama J, Miyagi Y, Seki N, et al: Serum
C-reactive protein as a prognostic factor in patients with
epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol.
82:107–110. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Asher V, Lee J, Innamaa A and Bali A:
Preoperative platelet lymphocyte ratio as an independent prognostic
marker in ovarian cancer. Clin Transl Oncol. 13:499–503. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cho H, Hur HW, Kim SW, et al:
Pre-treatment neutrophil to lymphocyte ratio is elevated in
epithelial ovarian cancer and predicts survival after treatment.
Cancer Immunol Immunother. 58:15–23. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kao SC, Pavlakis N, Harvie R, Vardy JL,
Boyer MJ, van Zandwijk N and Clarke SJ: High blood
neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in
malignant mesothelioma patients undergoing systemic therapy. Clin
Cancer Res. 16:5805–5813. 2010. View Article : Google Scholar : PubMed/NCBI
|
